公开(公告)号：US07763631B2

公开(公告)日：2010-07-27

申请号：US11225839

申请日：2005-09-13

申请人： Michael Joseph Kukla ,  Donald William Ludovici ,  Robert William Kavash ,  Bart Lieven Daniel De Corte ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Lucien Maria Henricus Koymans ,  Marc René de Jonge ,  Koen Jeanne Alfons Van Aken ,  Alain Krief

发明人： Michael Joseph Kukla ,  Donald William Ludovici ,  Robert William Kavash ,  Bart Lieven Daniel De Corte ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Lucien Maria Henricus Koymans ,  Marc René de Jonge ,  Koen Jeanne Alfons Van Aken ,  Alain Krief

IPC分类号： C07D401/12 ,  A61K31/444

CPC分类号： C07D239/47 ,  C07D239/48 ,  C07D401/12

摘要： The present invention concerns compounds of formula (A1)(A2)N—R1 (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein R1 is substituted C1-6alkyl; —S(═O)—R8; —S(═O)2—R8; C7-12alkylcarbonyl; optionally substituted C1-6alkyloxycarbonylC1-6alkylcarbonyl; with R8 being C1-6alkyl, aryl1 or Het1; (A1)(A2)N— is the covalently bonded form of the corresponding intermediate of formula (A1)(A2)N—H, which is a HIV replication inhibiting pyrimidine of formula

摘要翻译： 本发明涉及式（A1）（A2）（A2）（I）的化合物，N-氧化物形式，其药学上可接受的加成盐，季胺及其立体化学异构形式，其中R 1为取代的C 1-6烷基; -S（= O）-R8; -S（= O）2-R8; C7-12烷基羰基; 任选取代的C 1-6烷氧基羰基C 1-6烷基羰基; 其中R8是C1-6烷基，芳基或Het1; （A1）（A2）N-是式（A1）（A2）N-H的相应中间体的共价键合形式，其是式（I）的HIV复制抑制性嘧啶

公开(公告)号：US07015221B2

公开(公告)日：2006-03-21

申请号：US10649017

申请日：2003-08-27

申请人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

发明人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

IPC分类号： C07D251/16 ,  C07D251/18 ,  A61K31/53 ,  A61P31/18

CPC分类号： A61K9/146 ,  Y10S977/775 ,  Y10S977/915

摘要： This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl or substituted C1-6alkyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR4, —NH—S(═O)pR4, —C(═O)R4, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R4, —C(═NH)R4 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(=O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

公开(公告)号：US06638932B1

公开(公告)日：2003-10-28

申请号：US09831808

申请日：2001-08-02

申请人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

发明人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

IPC分类号： C07D25116

CPC分类号： A61K9/146 ,  Y10S977/775 ,  Y10S977/915

摘要： This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein —a1═a2—a3═a4— forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl or substituted C1-6alkyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR4, —NH—S(═O)pR4, —C(═O)R4, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R4, —C(═NH)R4 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; aryl is optionally substituted phenyl; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

摘要翻译： 本发明涉及配制N-氧化物的化合物，药学上可接受的加成盐，季胺及其立体化学异构形式的用途，其中-a 1 = a 2 -a 3 = a 4 - 与连接的乙烯基形成苯基，吡啶基，嘧啶基，哒嗪基或吡嗪基; n为0〜4; 并在可能的情况下5; R 1是氢，芳基，甲酰基，C 1-6烷基羰基，C 1-6烷基，C 1-6烷氧基羰基或取代的C 1-6烷基; 每个R 2独立地是羟基，卤素，任选取代的C 1-6烷基，C 2-6烯基或C 2-6炔基，C 3-7环烷基，C 1-6烷氧基，C 1-6烷氧基羰基，羧基，氰基，硝基，氨基，单或二（ C 1-6烷基）氨基，多卤代甲基，多卤甲氧基，多卤甲硫基，-S（= O）p R 4，-NH-S（= O）p R 4，-C（= O）R 4， = O）H，-C（= O）NHNH 2，-NHC（= O）R 4，-C（= NH）R 4或5元杂环; p为1或2; L是任选取代的C 1-10烷基，C 2-10烯基，C 2-10炔基或C 3-7环烷基; 或L是-X-R 3，其中R 3是任选取代的苯基，吡啶基，嘧啶基，吡嗪基或哒嗪基; X是-NR 1 - ， - NH-NH-，-N = N-，-O-，-C（= O） - ， - CHOH-，-S-，-S（= O） - 或 - S（= O）2-; 芳基是任选取代的苯基; 用于制造用于治疗患有HIV（人类免疫缺陷病毒）感染的受试者的药物。

公开(公告)号：US06197779B1

公开(公告)日：2001-03-06

申请号：US09276360

申请日：1999-03-25

申请人： Koenraad Jozef Lodewijk Marcel Andries ,  Bart De Corte ,  Marc René De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Marcel August Constant Janssen ,  Paul Adriaan Jan Janssen ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

发明人： Koenraad Jozef Lodewijk Marcel Andries ,  Bart De Corte ,  Marc René De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Marcel August Constant Janssen ,  Paul Adriaan Jan Janssen ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

IPC分类号： A61K31506

CPC分类号： C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/49 ,  C07D239/50 ,  C07D401/12

摘要： This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0 to 4; Q is hydrogen or —NR1R2; R1 and R2 are selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each C1-12alkyl may optionally be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl,; and R4 is hydroxy, halo, optionally substituted C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy; R5 is hydrogen or C1-4alkyl; L is optionally substituted C1-10alkyl, C3-10alkenyl, C3-10alkynyl, C3-7cycloalkyl; or L is —X1—R6 or —X2-Alk-R7 wherein R6 and R7 are optionally substituted phenyl; X1 and X2 are —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—; Alk is C1-4alkanediyl; aryl is potionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.

摘要翻译： 本发明涉及N-氧化物，其药学上可接受的加成盐和立体化学异构形式的化合物的用途，其中A是CH，CR 4或N; n为0〜4; Q是氢或-NR1R2; R1和R2选自氢，羟基，C1-12烷基，C1-12烷氧基，C1-12烷基羰基，C1-12烷氧基羰基，芳基，氨基，一或二（C1-12烷基）氨基，单或二（C1-12烷基） 其中每个C 1-12烷基可以任选被取代; 或R 1和R 2可以一起形成吡咯烷基，哌啶基，吗啉基，叠氮基或单或二（C 1-12烷基）氨基C 1-4亚烷基; R 3是氢，芳基，C 1-6烷基羰基，任选取代的C 1-6烷基，C 1-6烷氧基羰基。 R4为羟基，卤素，任选取代的C 1-6烷基，C 1-6烷氧基，氰基，氨基羰基，硝基，氨基，三卤代甲基，三卤代甲氧基; R5是氢或C1-4烷基; L是任选取代的C 1-10烷基，C 3-10烯基，C 3-10炔基，C 3-7环烷基; 或L是-X1-R6或-X2-Alk-R7，其中R6和R7是任选取代的苯基; X1和X2是-NR3-，-NH-NH-，-N = N-，-O - ， - S - ， - S（= O） - 或-S（= O） Alk是C1-4烷二基; 芳基是取代的苯基; Het是任选取代的脂族或芳族杂环基; 用于制造用于治疗患有HIV（人类免疫缺陷病毒）感染的受试者的药物。 它还涉及作为式（I）化合物的亚组的新化合物，其制备方法和包含它们的组合物。

公开(公告)号：US08530655B2

公开(公告)日：2013-09-10

申请号：US13177188

申请日：2011-07-06

申请人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken ,  Koenraad Jozef Lodewijk Marcel Andries ,  Frank Xavier Jozef Herwig Arts

发明人： Bart De Corte ,  Marc René de Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken ,  Koenraad Jozef Lodewijk Marcel Andries

IPC分类号： C07D401/12 ,  C07D403/12 ,  A61K31/506 ,  A61P31/18

CPC分类号： A61K31/505 ,  A61K31/5513

摘要： This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkylamino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

公开(公告)号：US20080176880A1

公开(公告)日：2008-07-24

申请号：US11930835

申请日：2007-10-31

申请人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

发明人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

IPC分类号： A61K31/505 ,  C07D239/42 ,  A61P31/18

CPC分类号： A61K31/505 ,  A61K31/5513

摘要： This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl; pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5. R1 is hydrogen, al, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═CO)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —C(—O)R6, —C(═NH)R6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

公开(公告)号：US6150360A

公开(公告)日：2000-11-21

申请号：US276362

申请日：1999-03-25

申请人： Frederik Frans Desire Daeyaert ,  Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici

发明人： Frederik Frans Desire Daeyaert ,  Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici

IPC分类号： A61K31/53 ,  A61P31/18 ,  C07D251/42 ,  C07D251/50 ,  C07D251/52 ,  C07D251/66 ,  C07D251/70 ,  C07D401/12 ,  C07D403/12 ,  C07D413/14 ,  C07D31/54

CPC分类号： C07D251/42 ,  C07D251/50 ,  C07D251/52 ,  C07D251/66 ,  C07D251/70 ,  C07D403/12

摘要： This invention concerns the use of the compounds of formula ##STR1## the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR.sup.4 or N; n is 0, 1, 2, 3 or 4; R.sup.1 and R.sup.2 are each independently selected from hydrogen, hydroxy, C.sub.1-12 alkyl, C.sub.1-12 alkyloxy, C.sub.1-12 alkylcarbonyl, C.sub.1-12 -alkyloxycarbonyl, aryl, amino, mono- or di(C.sub.1-12 alkyl)amino, mono- or di(C.sub.1-12 alkyl)aminocarbonyl wherein each of the aforementioned C.sub.1-12 alkyl groups may optionally and each individually be substituted; or R.sup.1 and R.sup.2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C.sub.1-12 alkyl)aminoC.sub.1-4 alkylidene; R.sup.3 is hydrogen, aryl, C.sub.1-6 alkylcarbonyl, optionally substituted C.sub.1-6 alkyl; and each R.sup.4 independently is hydroxy, halo, C.sub.1-6 alkyl, C.sub.1-6 -alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is --X--R.sup.5 or --X--Alk--R.sup.6 ; wherein R.sup.5 and R.sup.6 each independently are indanyl, indolyl or phenyl; each of said indanyl, indolyl or phenyl may be substituted; and X is --NR.sup.3 --, --NH--NH--, --N.dbd.N--, --O--, --S--, --S(.dbd.O)-- or --S(.dbd.O).sub.2 --; aryl is optionally substituted phenyl; Het is an optionally substituted aliphatic or aromatic heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and pharmaceutical compositions comprising them.

摘要翻译： 本发明涉及式I化合物在N-氧化物，其药学上可接受的加成盐和立体化学异构形式中的用途，其中A是CH，CR 4或N; n为0,1,2,3或4; R 1和R 2各自独立地选自氢，羟基，C 1-12烷基，C 1-12烷氧基，C 1-12烷基羰基，C 1-12烷氧基羰基，芳基，氨基，单或二（C 1-12烷基）氨基，单或二 C 1-12烷基）氨基羰基，其中每个上述C 1-12烷基可以任选地和各自独立地被取代; 或R 1和R 2可以一起形成吡咯烷基，哌啶基，吗啉基，叠氮基或单或二（C 1-12烷基）氨基C 1-4亚烷基; R3是氢，芳基，C1-6烷基羰基，任选取代的C 1-6烷基; 并且每个R 4独立地是羟基，卤素，C 1-6烷基，C 1-6 - 烷氧基，氰基，氨基羰基，硝基，氨基，三卤代甲基或三卤代甲氧基; L是-X-R5或-X-Alk-R6; 其中R 5和R 6各自独立地为茚满基，吲哚基或苯基; 所述二氢化茚基，吲哚基或苯基中的每一个可以被取代; 并且X是-NR 3 - ， - NH-NH - ， - N = N - ， - O - ， - S - ， - S（= O） - 或-S（= O） 芳基是任选取代的苯基; Het是任选取代的脂族或芳族杂环基; 用于制造用于治疗患有HIV（人类免疫缺陷病毒）感染的受试者的药物。 它还涉及作为式（I）化合物的亚组的新化合物，其制备方法和包含它们的药物组合物。

公开(公告)号：US07037917B2

公开(公告)日：2006-05-02

申请号：US10634682

申请日：2003-08-05

申请人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

发明人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

IPC分类号： C07D239/48 ,  A61K31/506 ,  A61P31/18

CPC分类号： A61K31/505 ,  A61K31/5513

摘要： This invention concerns the use of compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

公开(公告)号：US06878717B2

公开(公告)日：2005-04-12

申请号：US09430966

申请日：1999-11-01

申请人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

发明人： Bart De Corte ,  Marc Rene De Jonge ,  Jan Heeres ,  Chih Yung Ho ,  Paul Adriaan Jan Janssen ,  Robert W. Kavash ,  Lucien Maria Henricus Koymans ,  Michael Joseph Kukla ,  Donald William Ludovici ,  Koen Jeanne Alfons Van Aken

IPC分类号： C07D239/47 ,  A61K20060101 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/675 ,  A61K31/715 ,  A61P31/18 ,  C07D20060101 ,  C07D239/42 ,  C07D239/46 ,  C07D239/48 ,  C07D239/50 ,  C07D239/80 ,  C07D401/12 ,  C07D403/12

CPC分类号： A61K31/505 ,  A61K31/5513

摘要： This invention concerns the use of compounds of formula: the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=-a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or substituted C1-6alkyloxyC1-6alkylcarbonyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalo-methylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alkenyl, C2-10alkynyl or C3-7cycloalkyl; or L is —X—R3 wherein R3 is optionally substituted phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; Q is hydrogen, C1-6alkyl, halo, polyhalo-C1-6alkyl or an optionally substituted amino group; Y represents hydroxy, halo, C3-7cycloalkyl, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or aryl; aryl is optionally substituted phenyl; Het is an optionally substituted heterocyclic radical; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection.

摘要翻译： 本发明涉及下式化合物的用途：N-氧化物，药学上可接受的加成盐，季胺及其立体化学异构形式，其中-a 1 = -a 2 -a 3 = a < 与所连接的乙烯基形成苯基，吡啶基，嘧啶基，哒嗪基或吡嗪基; n为0〜4; 并在可能的情况下5; R 1是氢，芳基，甲酰基，C 1-6烷基羰基，C 1-6烷基，C 1-6烷氧基羰基，取代的C 1-6烷基或取代的C 1-6烷氧基C 1-6烷基羰基; 每个R 2独立地是羟基，卤素，任选取代的C 1-6烷基，C 2-6烯基或C 2-6炔基，C 3-7环烷基，C 1-6烷氧基，C 1-6烷氧基羰基，羧基，氰基，硝基，氨基，单或二（ C 1-6烷基）氨基，多卤代甲基，多卤甲氧基，多卤代甲硫基，-S（= O）p R 6，-NH-S（= O）p R 6，-C（= O）R 6， NHC（= O）H，-C（= O）NHNH 2，-NHC（= O）R 6，-C（= NH）R 6或5元杂环; p为1或2; L是任选取代的C 1-10烷基，C 2-10烯基，C 2-10炔基或C 3-7环烷基; 或L是-X-R 3，其中R 3是任选取代的苯基，吡啶基，嘧啶基，吡嗪基或哒嗪基; X是-NR 1 - ， - NH-NH-，-N = N-，-O-，-C（= O） - ， - CHOH-，-S-，-S（= O） - 或 - S（= O）2-; Q是氢，C 1-6烷基，卤素，多卤代-C 1-6烷基或任选取代的氨基; Y表示羟基，卤素，C 3-7环烷基，任选取代的C 1-6烷基，C 2-6烯基或C 2-6炔基，C 1-6烷氧基，C 1-6烷氧基羰基，羧基，氰基，硝基，氨基，单或二（C 1-6烷基）氨基 ，多卤甲基，多卤甲氧基，多卤甲硫基，-S（= O）pR 6，-NH-S（= O）pR 6，-C（= O）R 6，-NHC（= O） -C（= O）NHNH

公开(公告)号：US08088891B2

公开(公告)日：2012-01-03

申请号：US11576023

申请日：2005-09-28

申请人： Koenraad Jozef Lodewijk Marcel Andries ,  Hinrich Wilhelm Helmut Göhlmann ,  Jean-Marc Edmond Fernand Marie Neefs ,  Peter Karel Maria Verhasselt ,  Johann Winkler ,  Marc René De Jonge ,  Lucien Maria Henricus Koymans

发明人： Koenraad Jozef Lodewijk Marcel Andries ,  Hinrich Wilhelm Helmut Göhlmann ,  Jean-Marc Edmond Fernand Marie Neefs ,  Peter Karel Maria Verhasselt ,  Johann Winkler ,  Marc René De Jonge ,  Lucien Maria Henricus Koymans

IPC分类号： C07K14/00

CPC分类号： C07K14/35 ,  A61K38/00 ,  C12N9/14

摘要： This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.

摘要翻译： 本发明提供了一种分离的突变型atpE蛋白，并从所述突变型atpE蛋白中脱离鉴定ATP酶结合结构域。 本发明还提供了相关的核酸，载体，宿主细胞，药物组合物和制品。 本发明还提供了用于确定测试化合物是否与atpE蛋白（即与本发明的ATP酶结合结构域）相互作用的方法，以及包含所述测试化合物，特别是作为抗微生物剂的药物组合物，更特别地作为抗分枝杆菌剂，甚至 更具体地用于治疗受试者的结核病。